KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Short-term Investments: 2018-2020

Historic Short-term Investments for Elanco Animal Health (ELAN) over the last 2 years, with Dec 2020 value amounting to $11.0 million.

  • Elanco Animal Health's Short-term Investments fell 0.90% to $11.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $11.0 million, marking a year-over-year decrease of 0.90%. This contributed to the annual value of $11.0 million for FY2020, which is 0.90% down from last year.
  • Elanco Animal Health's Short-term Investments amounted to $11.0 million in Q4 2020, which was down 0.00% from $11.0 million recorded in Q3 2020.
  • Elanco Animal Health's Short-term Investments' 5-year high stood at $634.9 million during Q3 2018, with a 5-year trough of $11.0 million in Q1 2020.
  • Its 3-year average for Short-term Investments is $94.4 million, with a median of $11.1 million in 2019.
  • Data for Elanco Animal Health's Short-term Investments shows a maximum YoY plummeted of 98.25% (in 2019) over the last 5 years.
  • Over the past 3 years, Elanco Animal Health's Short-term Investments (Quarterly) stood at $202.7 million in 2018, then tumbled by 94.52% to $11.1 million in 2019, then fell by 0.90% to $11.0 million in 2020.
  • Its Short-term Investments stands at $11.0 million for Q4 2020, versus $11.0 million for Q3 2020 and $11.0 million for Q2 2020.